Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: EU approves Xenpozyme

( - Sanofi announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion and recommended the marketing of Xenpozyme.

The biopharmaceutical company said that this green light relates to the approval of Xenpozyme in the non-neurological manifestations of acid sphingomyelinase type A/B and type B deficiency.

The CHMP opinion is based on the positive results of two clinical trials that demonstrated that Xenpozyme improved respiratory function and reduced spleen and liver volume, with a well-tolerated safety profile.

Xenpozyme is a recombinant human enzyme developed to address the deficiency of acid sphingomyelinase, the enzyme that breaks down the lipid sphingomyelin.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.